Dr. Jon Cousin

Jon develops and executes worldwide patent strategies for life sciences and pharmaceutical companies. Working closely with his clients to understand their business and objectives, Jon helps them build robust, business-focused and diligence-ready patent portfolios. His practice includes developing patent strategies for drug-discovery and clinical programs, life cycle extension strategies, aligning patent and regulatory exclusivities, and Orange Book listings.

Jon has experience with new chemical entities, peptide therapeutics, polymorphs, formulations, 505(b)(2) products, antibody-drug conjugates, natural products, drug-device combos, biomaterials and manufacturing processes. Notable patent portfolios Jon has advised on include Epidiolex, Copiktra, Farydak, Arikayce, Amrix, Lamictal and Evekeo ODT, along with numerous candidates in clinical trials.

Jon also has significant experience conducting patentability, invalidity and freedom-to-operate analyses, along with company- and investor-side diligence for fundraisings, transactions and public offerings. He holds a PhD in organic chemistry and was previously in-house counsel at a technology transfer office.

Speaking engagements

• Co-presenter, “505(b)(2) Applications and Beyond: Prosecution and Litigation Strategies for Filing and Defending Against 505(b)(2) NDAs,” Cooley Rx series, October 2024
• Co-presenter, “Planning for the Future: Aligning Prosecution and Litigation Strategies,” Cooley Rx series, September 2024